GSK Australia reports 2020 results to ASIC, May 2021
Read more - GSK Australia reports 2020 results to ASIC, May 2021 Read more
Press releases
These press releases are intended for business journalists and analysts/investors
GSK Supports the Uluru Statement from the Heart March 2021
Read more - GSK Supports the Uluru Statement from the Heart March 2021 Read more
Triathlete turned scientist wins major research award for uncovering potential obesity and diabetes treatment
Following decision announced in July, GSK confirms Boronia manufacturing site to close at end of 2022
GSK welcomes new Meningococcal B program to help protect those most at risk
GSK Australia today welcomed the addition of Meningococcal B (MenB) vaccination for Aboriginal and Torres Strait Islander infants to the National Immunisation Program (NIP)1 as well as people of all ages with some medical conditions that increase their risk of Invasive Meningococcal Disease (IMD).
Read more - GSK welcomes new Meningococcal B program to help protect those most at risk Read more
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK Australia today announced that a new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for severe eosinophilic asthma patients, NUCALA (mepolizumab), will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) from 1 June 2020.
GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2019 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, and ViiV Healthcare Australia (a joint venture with Pfizer and Shionogi focused on HIV). GSK Australia’s Consumer Healthcare business will report separately in the coming months.
Read more - GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC Read more
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021
GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer
GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer, following an agreement reached with Takeda Australia. This transfer of marketing authorisation is an important first step in the process for GSK to make this medicine available to Australian patients.
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
